Ha M - Search Results

1

Overexpression of ECT2 is a strong poor prognostic factor in ER(+) breast cancer.

Xiu Y, Liu W, Wang T, Liu Y, Ha M. Xiu Y, et al. Among authors: ha m. Mol Clin Oncol. 2019 May;10(5):497-505. doi: 10.3892/mco.2019.1832. Epub 2019 Mar 20. Mol Clin Oncol. 2019. PMID: 30967944 Free PMC article.

2

Clinical significance of GRHL3 expression in diffuse large B cell lymphoma.

Liu W, Ha M, Wang X, Yin N. Liu W, et al. Among authors: ha m. Tumour Biol. 2016 Jul;37(7):9657-61. doi: 10.1007/s13277-015-4772-5. Epub 2016 Jan 22. Tumour Biol. 2016. PMID: 26797800

3

Prognostic significance of subclassification of stage IIB lung cancer: a retrospective study of 226 patients.

Yin N, Ha M, Liu Y, Gu H, Zhang Z, Liu W. Yin N, et al. Among authors: ha m. Oncotarget. 2017 Jul 11;8(28):45777-45783. doi: 10.18632/oncotarget.17405. Oncotarget. 2017. PMID: 28501856 Free PMC article.

4

Combination of platelet count and lymphocyte to monocyte ratio is a prognostic factor in patients undergoing surgery for non-small cell lung cancer.

Liu W, Ha M, Yin N. Liu W, et al. Among authors: ha m. Oncotarget. 2017 Jun 1;8(42):73198-73207. doi: 10.18632/oncotarget.18336. eCollection 2017 Sep 22. Oncotarget. 2017. PMID: 29069863 Free PMC article.

5

Silencing ARHGAP9 correlates with the risk of breast cancer and inhibits the proliferation, migration, and invasion of breast cancer.

Wang T, Ha M. Wang T, et al. Among authors: ha m. J Cell Biochem. 2018 Sep;119(9):7747-7756. doi: 10.1002/jcb.27127. Epub 2018 Jun 15. J Cell Biochem. 2018. Retraction in: J Cell Biochem. 2021 Dec;122(12):1976. doi: 10.1002/jcb.30184 PMID: 29905031 Retracted.

6

A C118T polymorphism of ERCC1 and response to cisplatin chemotherapy in patients with late-stage non-small cell lung cancer.

Cheng J, Ha M, Wang Y, Sun J, Chen J, Wang Y, Tong C. Cheng J, et al. Among authors: ha m. J Cancer Res Clin Oncol. 2012 Feb;138(2):231-8. doi: 10.1007/s00432-011-1090-1. Epub 2011 Nov 20. J Cancer Res Clin Oncol. 2012. PMID: 22102173

7

The role of expression and polymorphism of the BAG-1 gene in response to platinum-based chemotherapeutics in NSCLC.

Wang YD, Ha MW, Cheng J, Zhang WL, Cong X, Tong CY, Sun J. Wang YD, et al. Oncol Rep. 2012 Apr;27(4):979-86. doi: 10.3892/or.2011.1591. Epub 2011 Dec 13. Oncol Rep. 2012. PMID: 22179630 Free PMC article.

8

Elevated pretreatment serum concentration of YKL-40: an independent prognostic biomarker for poor survival in patients with colorectal cancer.

Liu X, Zhang Y, Zhu Z, Ha M, Wang Y. Liu X, et al. Among authors: ha m. Med Oncol. 2014 Aug;31(8):85. doi: 10.1007/s12032-014-0085-6. Epub 2014 Jul 5. Med Oncol. 2014. PMID: 24996799

9

Role of BCL2-associated athanogene in resistance to platinum-based chemotherapy in non-small-cell lung cancer.

Wang Y, Ha M, Liu J, Li P, Zhang W, Zhang X. Wang Y, et al. Among authors: ha m. Oncol Lett. 2016 Feb;11(2):984-990. doi: 10.3892/ol.2015.4003. Epub 2015 Dec 4. Oncol Lett. 2016. PMID: 26893680 Free PMC article.

10

Association of single nucleotide polymorphisms in the MVP gene with platinum resistance and survival in patients with epithelial ovarian cancer.

Zhao YN, He DN, Wang YD, Li JJ, Ha MW. Zhao YN, et al. Oncol Lett. 2016 Apr;11(4):2925-2933. doi: 10.3892/ol.2016.4311. Epub 2016 Mar 8. Oncol Lett. 2016. PMID: 27073578 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,167 results

Search Page

Filters